283 related articles for article (PubMed ID: 16176495)
1. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
Matchar DB; Samsa GP; Liu S
Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
[TBL] [Abstract][Full Text] [Related]
2. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
8. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
Schleinitz MD; Weiss JP; Owens DK
Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
[TBL] [Abstract][Full Text] [Related]
10. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
11. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Sarasin FP; Gaspoz JM; Bounameaux H
Arch Intern Med; 2000 Oct; 160(18):2773-8. PubMed ID: 11025787
[TBL] [Abstract][Full Text] [Related]
13. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Ringborg A; Lindgren P; Jönsson B
Eur J Health Econ; 2005 Dec; 6(4):354-6, 358-62. PubMed ID: 16267654
[TBL] [Abstract][Full Text] [Related]
16. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
Bath PM; Cotton D; Martin RH; Palesch Y; Yusuf S; Sacco R; Diener HC; Estol C; Roberts R;
Stroke; 2010 Apr; 41(4):732-8. PubMed ID: 20181679
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
Weimar C; Cotton D; Sha N; Sacco RL; Bath PM; Weber R; Diener HC
Cerebrovasc Dis; 2013; 35(6):538-43. PubMed ID: 23816610
[TBL] [Abstract][Full Text] [Related]
18. Counting the true cost of antiplatelet therapy for stroke prevention.
Morton JA; Newton J; Gray CS
Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
[No Abstract] [Full Text] [Related]
19. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
Rothlisberger JM; Ovbiagele B
J Comp Eff Res; 2015 Aug; 4(4):377-84. PubMed ID: 26274799
[TBL] [Abstract][Full Text] [Related]
20. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]